Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ARDM
- CUSIP: N/A
- Web: www.aradigm.com
Capitalization:- Market Cap: $38.23 million
- Outstanding Shares: 14,430,000
Average Prices:- 50 Day Moving Avg: $1.32
- 200 Day Moving Avg: $1.39
- 52 Week Range: $0.78 - $7.19
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.33
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $9.54 million
- Price / Sales: 3.83
- Book Value: ($0.42) per share
- Price / Book: -6.02
Profitability:- EBIDTA: ($14,990,000.00)
- Net Margins: -196.65%
- Return on Equity: -665.03%
- Return on Assets: -83.01%
Debt:- Debt-to-Equity Ratio: -2.34%
- Current Ratio: 2.52%
- Quick Ratio: 2.52%
Misc:- Average Volume: 34,986 shs.
- Beta: 1.22
- Short Ratio: 1.39
Frequently Asked Questions for Aradigm Corporation (NASDAQ:ARDM)
What is Aradigm Corporation's stock symbol?
Aradigm Corporation trades on the NASDAQ under the ticker symbol "ARDM."
How were Aradigm Corporation's earnings last quarter?
Aradigm Corporation (NASDAQ:ARDM) released its earnings results on Thursday, August, 10th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.37. The firm earned $7.68 million during the quarter. Aradigm Corporation had a negative net margin of 196.65% and a negative return on equity of 665.03%. View Aradigm Corporation's Earnings History.
When will Aradigm Corporation make its next earnings announcement?
Who are some of Aradigm Corporation's key competitors?
Some companies that are related to Aradigm Corporation include Pfenex (PFNX), Ergomed PLC (ERGO), Rexahn Pharmaceuticals (RNN), ImmuPharma PLC (IMM), Applied Genetic Technologies Corporation (AGTC), Motif Bio PLC (MTFB), Flex Pharma (FLKS), Egalet Corporation (EGLT), TRACON Pharmaceuticals (TCON), Endocyte (ECYT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE), OptiBiotix Health PLC (OPTI), Capricor Therapeutics (CAPR), pSivida Corp. (PSDV) and Proteostasis Therapeutics (PTI).
Who are Aradigm Corporation's key executives?
Aradigm Corporation's management team includes the folowing people:
- Virgil D. Thompson, Independent Chairman of the Board
- Igor Gonda Ph.D., President, Chief Executive Officer, Director
- Nancy E. Pecota, Chief Financial Officer, Vice President - Finance
- Juergen Froehlich, Chief Medical Officer
- David Bell, Director
- Frederick M. Hudson CPA, Independent Director
- John M. Siebert Ph.D., Independent Director
Who owns Aradigm Corporation stock?
Who sold Aradigm Corporation stock? Who is selling Aradigm Corporation stock?
How do I buy Aradigm Corporation stock?
Shares of Aradigm Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aradigm Corporation's stock price today?
One share of Aradigm Corporation stock can currently be purchased for approximately $2.53.
MarketBeat Community Rating for Aradigm Corporation (NASDAQ ARDM)MarketBeat's community ratings are surveys of what our community members think about Aradigm Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Aradigm Corporation (NASDAQ:ARDM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $10.00 (295.26% upside) |
Analysts' Ratings History for Aradigm Corporation (NASDAQ:ARDM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/25/2017 | Ladenburg Thalmann Financial Services | Reiterated Rating | Buy | $7.50 -> $10.00 | Medium |  |
(Data available from 9/26/2015 forward)
Earnings History for Aradigm Corporation (NASDAQ:ARDM)Earnings History by Quarter for Aradigm Corporation (NASDAQ ARDM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.31) | | | | | N/A | |
| 8/10/2017 | Q2 2017 | ($0.30) | $0.07 | | $7.68 million | View | N/A | |
| 5/15/2017 | Q1 2017 | ($0.43) | ($0.25) | | $1.69 million | View | N/A | |
| 3/28/2017 | Q4 2016 | ($0.37) | ($0.54) | | $0.13 million | View | N/A | |
| 11/9/2016 | Q3 2016 | ($0.53) | ($0.55) | | $0.05 million | View | N/A | |
| 8/10/2016 | Q2 | ($0.59) | ($0.59) | | $0.01 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.59) | ($0.55) | | $0.01 million | View | N/A | |
| 3/15/2016 | Q415 | ($0.55) | ($0.63) | | $0.04 million | View | N/A | |
| 11/11/2015 | Q3 | ($0.19) | ($0.38) | | $4.67 million | View | N/A | |
| 8/13/2015 | Q2 | ($0.08) | ($0.08) | $11.60 million | $10.00 million | View | N/A | |
| 5/11/2015 | Q1 | ($0.06) | ($0.08) | | $8.77 million | View | N/A | |
| 3/17/2015 | Q414 | ($0.07) | ($0.06) | $6.70 million | $8.10 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.10) | ($0.06) | $4.80 million | $6.60 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.09) | ($0.09) | $4.25 million | $12.20 million | View | N/A | |
| 10/28/2013 | Q3 13 | | ($0.04) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aradigm Corporation (NASDAQ:ARDM)Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS
Dividend History for Aradigm Corporation (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aradigm Corporation (NASDAQ:ARDM)Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 33.64%
Insider Trades by Quarter for Aradigm Corporation (NASDAQ:ARDM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/4/2017 | Juergen Kurt Froehlich | Insider | Sell | 3,765 | $1.51 | $5,685.15 | |
| 10/4/2016 | Juergen Kurt Froehlich | Insider | Sell | 423 | $6.76 | $2,859.48 | |
| 6/21/2016 | Juergen Kurt Froehlich | Insider | Sell | 333 | $4.45 | $1,481.85 | |
| 12/13/2013 | Virgil Thompson | Director | Sell | 3,340 | $0.17 | $567.80 | |
| 8/27/2013 | First Eagle Investment Managem | Major Shareholder | Buy | 40,322,580 | $0.12 | $4,838,709.60 | |
| 12/11/2012 | First Eagle Investment Managem | Major Shareholder | Buy | 41,666,667 | $0.12 | $5,000,000.04 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aradigm Corporation (NASDAQ:ARDM)
Latest Headlines for Aradigm Corporation (NASDAQ:ARDM)
| Source: |
|
| Date | Headline |
|---|
 | Aradigm Corporation (ARDM) Receives "Buy" Rating from Ladenburg Thalmann Financial Services
www.americanbankingnews.com - September 25 at 6:00 PM |
 | 20 Biggest Mid-Day Gainers For Monday
feeds.benzinga.com - September 25 at 1:40 PM |
 | Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
finance.yahoo.com - September 22 at 1:25 PM |
| Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients
finance.yahoo.com - September 15 at 4:22 PM |
| Aradigm Corporation (ARDM) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - September 13 at 4:16 PM |
| Aradigm Corporation (ARDM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - September 12 at 10:39 PM |
| Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress
finance.yahoo.com - September 5 at 5:40 PM |
| Aradigm Corporation (ARDM) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - September 5 at 4:10 PM |
| Aradigm Corporation (ARDM) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 4 at 4:32 PM |
| Aradigm Corporation (ARDM) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - August 30 at 4:23 PM |
| Aradigm Corporation (ARDM) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 24 at 4:34 PM |
 | Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term ...
www.nasdaq.com - August 15 at 4:59 PM |
| Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq
finance.yahoo.com - August 15 at 4:59 PM |
| Aradigm Corporation (NASDAQ:ARDM) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS
www.americanbankingnews.com - August 11 at 2:42 PM |
| Aradigm Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 5:26 PM |
| Aradigm posts 2Q profit
finance.yahoo.com - August 10 at 5:26 PM |
| Aradigm Corporation (NASDAQ:ARDM) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
 | Aradigm Corp. (ARDM) Submits NDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
www.streetinsider.com - July 29 at 8:45 PM |
| Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
finance.yahoo.com - July 27 at 4:05 PM |
| Aradigm Corporation (ARDM) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 5:26 PM |
 | BRIEF-Aradigm Corp presents analysis of results for phase 3 orbit-3, orbit-4 clinical trials
www.businessinsider.com - July 8 at 3:41 PM |
 | Quietly, Spanish company makes fifth Bay Area biotech investment in 4 years
www.bizjournals.com - July 8 at 6:22 AM |
| Aradigm Co. (ARDM) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - June 5 at 4:22 PM |
| Head-To-Head Analysis: IntelliPharmaCeutics Intl (IPCI) & Aradigm (ARDM)
www.americanbankingnews.com - June 5 at 8:01 AM |
| Aradigm Co. (ARDM) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 23 at 4:24 PM |
| Aradigm Co. (ARDM) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 3:24 PM |
| Aradigm Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 4:04 PM |
| Aradigm reports 1Q loss
finance.yahoo.com - May 15 at 4:04 PM |
| Short Interest in Aradigm Co. (ARDM) Expands By 25.8%
www.americanbankingnews.com - May 15 at 8:48 AM |
| Aradigm Co. (ARDM) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:12 PM |
| Aradigm Co. (ARDM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 10:46 PM |
| Aradigm Co. (ARDM) Set to Announce Earnings on Monday
www.americanbankingnews.com - May 5 at 10:23 PM |
| Somewhat Favorable Press Coverage Very Likely to Impact Aradigm (ARDM) Share Price
www.americanbankingnews.com - April 27 at 2:44 PM |
| ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 30 at 9:04 PM |
 | Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
us.rd.yahoo.com - March 28 at 3:37 PM |
| Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
finance.yahoo.com - February 9 at 3:40 PM |
| Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9
finance.yahoo.com - January 6 at 3:43 PM |
| ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - December 6 at 12:40 PM |
 | Aradigm's Inhaled Antibiotic Fails Study (ARDM)
www.investopedia.com - December 3 at 8:44 AM |
| Aradigm Lung Infection Antibiotic Fails Trial (ARDM)
www.investopedia.com - December 2 at 9:01 PM |
 | Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections ...
www.businesswire.com - December 1 at 3:41 PM |
| Mid-Day Market Update: Crude Oil Up Over 4%; Express Shares Fall On Weak Outlook
www.nasdaq.com - December 1 at 3:41 PM |
| Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment …
finance.yahoo.com - December 1 at 3:41 PM |
| 7:03 am Aradigm announces top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin (shares halted)
us.rd.yahoo.com - December 1 at 3:41 PM |
| Aradigm posts mixed late-stage data on inhaled antibiotic
finance.yahoo.com - December 1 at 3:41 PM |
 | Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials
www.marketwatch.com - December 1 at 3:41 PM |
 | Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin
www.thestreet.com - December 1 at 3:41 PM |
 | What's In The Offing For These Biotech Stocks?
www.rttnews.com - November 22 at 12:39 PM |
| ARADIGM CORP Financials
finance.yahoo.com - November 18 at 3:35 PM |
| Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16
finance.yahoo.com - November 10 at 2:05 PM |
Aradigm Corporation (ARDM) Chart for Tuesday, September, 26, 2017
